Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online December 27, 2007
Diabetes Care 31:442-444, 2008
DOI: 10.2337/dc07-1739
© 2008 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-1739v1
31/3/442    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Lopez, X.
Right arrow Articles by Goldfine, A. B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lopez, X.
Right arrow Articles by Goldfine, A. B.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Clinical Care/Education/Nutrition/Psychosocial Research
Original Research

Human Insulin Analog–Induced Lipoatrophy

Ximena Lopez, MD1,3, Mariana Castells, MD2,3, Alyne Ricker, MD1,3, Elsa F. Velazquez, MD2,3, Edward Mun, MD2,3 and Allison B. Goldfine, MD1,2,3

1 Joslin Diabetes Center, Boston, Massachusetts
2 Brigham and Woman’s Hospital, Boston, Massachusetts
3 Harvard Medical School, Boston, Massachusetts

Address correspondence and reprint requests to Allison Goldfine, One Joslin Place, Boston, MA 02215. E-mail: allison.goldfine{at}joslin.harvard.edu

OBJECTIVE—To characterize the pathophysiology of recombinant human insulin-induced lipoatrophy.

RESEARCH DESIGN AND METHODS—We performed immunologic laboratory evaluation and skin testing for different insulin analogs and diluents in patients with type 1 diabetes and severe insulin-induced local lipoatrophy. Subcutaneous adipose tissue biopsies of areas of acute (7 days) and chronic insulin administration were examined. Topical sodium cromolyn was applied twice a day to atrophic areas and prophylactically to new sites of insulin administration.

RESULTS—Subcutaneous adipose biopsies showed an elevated population of tryptase-positive, chymase-positive degranulated mast cells. Of five patients treated with topical sodium cromolyn, none had new lipoatrophic sites and four showed improvements in old lesions.

CONCLUSIONS—Tryptase-positive/chymase-postitive mast cells, known to be sensitive to sodium cromolyn, may contribute to the destructive immune process mediated in response to exogenous insulin. Mast cell stabilizing therapy with topical cromolyn may reverse early and prevent new lipoatrophic lesions.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.